A 45-year-old man presents to the emergency department with complaint of dizziness and nausea for the past hour. He says that he can feel his heartbeat racing. He also reports of generalized weakness that began in the morning. He was diagnosed with end-stage renal disease 2 years ago and currently on dialysis, but he missed his last dialysis session. He has also been diabetic for the past 15 years and managed with insulin, and was also diagnosed with celiac disease 8 years ago. He does not smoke or drink alcohol. The family history is insignificant. The temperature is 36.7°C (98.0°F), blood pressure is 145/90 mm Hg, pulse is 87/min, and respiratory rate is 14/min. On physical examination, the patient looks fatigued and exhausted. The muscle strength in the lower limbs is 4/5 bilaterally. An ECG is ordered which shows peaked and narrow T waves and prolongation of PR interval. The lab test results are as follows:
Serum Sodium 132 mEq/L
Serum Potassium 8 mEq/L
Serum Creatinine 5 mg/dL
Blood urea nitrogen (BUN) 25 mg/dL
What is the mechanism of action of the most likely initial treatment for the patient's condition?
Q812
A 4-day-old boy is monitored in the well baby nursery. He was born to a G1P1 mother at 36 weeks gestation. The child is doing well, and the mother is recovering from vaginal delivery. On physical exam, there is an arousable infant who is crying vigorously and is mildly cyanotic. A red reflex is noted bilaterally on ophthalmologic exam. The infant's fontanelle is soft, and his sucking reflex is present. A positive Babinski sign is noted on physical exam bilaterally. A continuous murmur is auscultated on cardiac exam. Which of the following would most likely have prevented the abnormal finding in this infant?
Q813
A 52-year-old woman presents to the emergency room complaining of chest pain. She reports a 4-hour history of dull substernal pain radiating to her jaw. Her history is notable for hypertension, diabetes mellitus, and alcohol abuse. She has a 30 pack-year smoking history and takes lisinopril and metformin but has an allergy to aspirin. Her temperature is 99.1°F (37.3°C), blood pressure is 150/90 mmHg, pulse is 120/min, and respirations are 22/min. Physical examination reveals a diaphoretic and distressed woman. An electrocardiogram reveals ST elevations in leads I, aVL, and V5-6. She is admitted with plans for immediate transport to the catheterization lab for stent placement. What is the mechanism of the next medication that should be given to this patient?
Q814
A 55-year-old man comes to the physician because of difficulties achieving an erection for the past year. A medication is prescribed that inhibits cyclic GMP phosphodiesterase type 5. Which of the following is the most likely site of action of the prescribed drug?
Q815
A 30-year-old man presents to his psychiatrist for a follow-up visit. He was diagnosed with schizophrenia 6 months ago and has been taking fluphenazine. He says that his symptoms are well controlled by the medication, and he no longer has auditory hallucinations. The psychiatrist also notes that his delusions and other psychotic symptoms have improved significantly. However, the psychiatrist notices something while talking to the patient that prompts him to say, “I know the drug has effectively controlled your symptoms but I think you should discontinue it now otherwise this side effect is likely to be irreversible.” Which of the following did the psychiatrist most likely notice in this patient?
Q816
A 72-year-old woman is brought to the emergency department by her son after he noticed that she was slurring her speech. He also noticed that she appeared to have difficulty using her fork about halfway through dinner when the speech problems started. He brought her to the emergency department immediately and he estimates that only 1 hour has passed since the beginning of the symptoms. An immediate exam is conducted. A medication is administered to ameliorate the effects of this patient's condition that would not be available for use if the patient had presented significantly later. An hour later the patient's condition becomes significantly worse and new deficits are found. Which of the following agents should be used at this point?
Q817
A 35-year-old woman is started on a new experimental intravenous drug X. In order to make sure that she is able to take this drug safely, the physician in charge of her care calculates the appropriate doses to give to this patient. Data on the properties of drug X from a subject with a similar body composition to the patient is provided below:
Weight: 100 kg
Dose provided: 1500 mg
Serum concentration 15 mg/dL
Bioavailability: 1
If the patient has a weight of 60 kg and the target serum concentration is 10 mg/dL, which of the following best represents the loading dose of drug X that should be given to this patient?
Q818
A 36-year-old man is brought to the emergency department by his girlfriend because of increasing confusion for the past 6 hours. He drinks large amounts of alcohol daily and occasionally uses illicit drugs. He is lethargic and oriented only to person. Physical examination shows jaundice, hepatomegaly, and scattered petechiae over the trunk and back. Neurologic examination shows normal, reactive pupils and a flapping tremor when the wrists are extended. A drug with which of the following mechanism of action would be most appropriate for this patient's condition?
Q819
A 25-year-old G1P0 woman at an estimated gestational age of 9 weeks presents for her first prenatal visit following a positive home pregnancy test. She says she missed 2 periods but assumed it was due to stress at work. She has decided to continue with the pregnancy. Her past medical history is significant for migraine headaches, seizures, and asthma. She takes multiple medications for her condition. Physical examination is unremarkable. An ultrasound confirms a 9-week-old intrauterine pregnancy. Which of the following medications poses the greatest risk to the fetus?
Q820
A 62-year-old woman with a history of subarachnoid hemorrhage is brought to the emergency department because of shortness of breath and sharp chest pain that worsens on inspiration. She underwent surgery for a hip fracture 3 weeks ago. Her pulse is 110/min, respirations are 20/min, and blood pressure is 112/74 mm Hg. Pulse oximetry on room air shows an oxygen saturation of 92%. The lungs are clear to auscultation and there is no jugular venous distention. A ventilation and perfusion scan shows a small perfusion defect in the left lower lung. A drug with which of the following mechanisms of action is most appropriate for this patient?
Autonomic/CV Drugs US Medical PG Practice Questions and MCQs
Question 811: A 45-year-old man presents to the emergency department with complaint of dizziness and nausea for the past hour. He says that he can feel his heartbeat racing. He also reports of generalized weakness that began in the morning. He was diagnosed with end-stage renal disease 2 years ago and currently on dialysis, but he missed his last dialysis session. He has also been diabetic for the past 15 years and managed with insulin, and was also diagnosed with celiac disease 8 years ago. He does not smoke or drink alcohol. The family history is insignificant. The temperature is 36.7°C (98.0°F), blood pressure is 145/90 mm Hg, pulse is 87/min, and respiratory rate is 14/min. On physical examination, the patient looks fatigued and exhausted. The muscle strength in the lower limbs is 4/5 bilaterally. An ECG is ordered which shows peaked and narrow T waves and prolongation of PR interval. The lab test results are as follows:
Serum Sodium 132 mEq/L
Serum Potassium 8 mEq/L
Serum Creatinine 5 mg/dL
Blood urea nitrogen (BUN) 25 mg/dL
What is the mechanism of action of the most likely initial treatment for the patient's condition?
A. Prevents platelet aggregation
B. Blocks beta adrenergic receptors
C. Antagonizes the membrane action of hyperkalemia (Correct Answer)
D. Increase potassium loss from the gastrointestinal tract
E. Blocks Na+/K+ ATPase
Explanation: ***Antagonizes the membrane action of hyperkalemia***
- The patient's presentation with **dizziness**, **nausea**, **racing heartbeat**, **generalized weakness**, **missed dialysis**, and ECG findings of **peaked T waves** and **prolonged PR interval** are classic for **severe hyperkalemia** (potassium 8 mEq/L).
- The most immediate and life-saving initial treatment for hyperkalemia with ECG changes is **intravenous calcium (e.g., calcium gluconate or calcium chloride)**, which **stabilizes the cardiac myocyte membrane** by antagonizing the direct membrane effects of elevated potassium, without lowering serum potassium levels.
*Prevents platelet aggregation*
- This is the mechanism of action for **antiplatelet drugs** like aspirin or clopidogrel, which are used to prevent thrombus formation in conditions like myocardial infarction or stroke.
- Platelet aggregation is not the primary issue in acute hyperkalemia.
*Blocks beta adrenergic receptors*
- This is the mechanism of action of **beta-blockers**, used to treat conditions like hypertension, angina, and certain arrhythmias.
- Beta-blockers are not indicated for the immediate treatment of hyperkalemia.
*Increase potassium loss from the gastrointestinal tract*
- This is the mechanism of action of **potassium binders** such as sodium polystyrene sulfonate (Kayexalate) or patiromer.
- While these can lower potassium, their action is much slower and not the initial life-saving intervention needed in severe hyperkalemia with ECG changes.
*Blocks Na+/K+ ATPase*
- This is the mechanism of action of **cardiac glycosides** like **digoxin**, which increase intracellular calcium and myocardial contractility.
- Blocking the Na+/K+ ATPase can worsen hyperkalemia (as Na+/K+ ATPase normally pumps K+ into cells) and is not a treatment for hyperkalemia.
Question 812: A 4-day-old boy is monitored in the well baby nursery. He was born to a G1P1 mother at 36 weeks gestation. The child is doing well, and the mother is recovering from vaginal delivery. On physical exam, there is an arousable infant who is crying vigorously and is mildly cyanotic. A red reflex is noted bilaterally on ophthalmologic exam. The infant's fontanelle is soft, and his sucking reflex is present. A positive Babinski sign is noted on physical exam bilaterally. A continuous murmur is auscultated on cardiac exam. Which of the following would most likely have prevented the abnormal finding in this infant?
A. Prostaglandins
B. Indomethacin (Correct Answer)
C. Folic acid
D. Betamethasone
E. Oxygen therapy
Explanation: ***Indomethacin***
- The continuous murmur and mild cyanosis in a premature infant (36 weeks gestation) suggest a **patent ductus arteriosus (PDA)**.
- **Prophylactic indomethacin** given to premature infants shortly after birth can prevent the development of a symptomatic PDA by inhibiting prostaglandin synthesis, which promotes ductal closure.
- Indomethacin, a **prostaglandin inhibitor**, prevents prostaglandin-mediated vasodilation and facilitates closure of the ductus arteriosus in the early postnatal period.
- This is particularly important in premature infants who are at higher risk for persistent PDA due to immature ductal responsiveness.
*Prostaglandins*
- **Prostaglandins** (specifically PGE1) are used to *keep* the ductus arteriosus open, which is desirable in certain cyanotic congenital heart defects that require ductal patency for systemic or pulmonary blood flow (e.g., transposition of great arteries, pulmonary atresia).
- Administering prostaglandins in this case would worsen the **patent ductus arteriosus** by preventing its closure.
*Folic acid*
- **Folic acid** supplementation during pregnancy is crucial for preventing neural tube defects such as spina bifida and anencephaly.
- It has no role in preventing or treating a **patent ductus arteriosus** or other cardiovascular abnormalities in newborns.
*Betamethasone*
- **Betamethasone** is a corticosteroid given to pregnant mothers at risk of preterm delivery (between 24-34 weeks) to accelerate fetal lung maturity and reduce respiratory distress syndrome.
- While it improves neonatal outcomes in premature infants, it does not directly prevent the development of **patent ductus arteriosus**.
*Oxygen therapy*
- **Oxygen therapy** is used to treat hypoxemia and improve tissue oxygenation in cyanotic infants.
- While increased oxygen tension can contribute to ductal constriction, oxygen therapy alone is not a primary or reliable preventative measure for PDA in premature infants.
- Indomethacin remains the definitive pharmacologic intervention for prevention of symptomatic PDA.
Question 813: A 52-year-old woman presents to the emergency room complaining of chest pain. She reports a 4-hour history of dull substernal pain radiating to her jaw. Her history is notable for hypertension, diabetes mellitus, and alcohol abuse. She has a 30 pack-year smoking history and takes lisinopril and metformin but has an allergy to aspirin. Her temperature is 99.1°F (37.3°C), blood pressure is 150/90 mmHg, pulse is 120/min, and respirations are 22/min. Physical examination reveals a diaphoretic and distressed woman. An electrocardiogram reveals ST elevations in leads I, aVL, and V5-6. She is admitted with plans for immediate transport to the catheterization lab for stent placement. What is the mechanism of the next medication that should be given to this patient?
A. Cyclooxygenase activator
B. ADP receptor inhibitor (Correct Answer)
C. Phosphodiesterase activator
D. Thrombin inhibitor
E. Vitamin K epoxide reductase inhibitor
Explanation: ***ADP receptor inhibitor***
- This patient is experiencing an **ST-elevation myocardial infarction (STEMI)** as evidenced by ST elevations in leads I, aVL, and V5-6 (lateral wall infarction)
- **Dual antiplatelet therapy** is the standard of care for STEMI, typically consisting of aspirin plus a P2Y12 inhibitor (ADP receptor inhibitor)
- Since this patient has an **aspirin allergy**, an ADP receptor inhibitor such as **clopidogrel, ticagrelor, or prasugrel** becomes the critical next antiplatelet medication
- These agents **irreversibly or reversibly block the P2Y12 receptor** on platelets, preventing ADP-mediated platelet activation and aggregation
- This is essential for preventing further thrombotic complications during and after percutaneous coronary intervention (PCI)
*Cyclooxygenase activator*
- No cyclooxygenase activator exists in clinical practice for cardiovascular disease
- Aspirin works as a **cyclooxygenase inhibitor**, blocking COX-1 to prevent thromboxane A2 synthesis, but the patient is allergic to aspirin
- "Activating" cyclooxygenase would promote platelet aggregation, which is counterproductive in acute MI
*Phosphodiesterase activator*
- Phosphodiesterase activation would decrease cAMP/cGMP levels, which is not therapeutically beneficial
- **Phosphodiesterase inhibitors** (such as cilostazol or dipyridamole) can have antiplatelet effects by increasing cAMP, but they are not first-line agents for acute STEMI
- An activator would have the opposite and undesirable effect
*Thrombin inhibitor*
- Thrombin inhibitors (e.g., **bivalirudin, heparin**) are anticoagulants that prevent conversion of fibrinogen to fibrin
- While **anticoagulation is important in STEMI management**, it is used as adjunctive therapy alongside antiplatelet agents
- Given the aspirin allergy, the immediate priority is **antiplatelet therapy with an ADP receptor inhibitor**
- Anticoagulation would typically be given concurrently but is not "the next" critical medication in this specific context
*Vitamin K epoxide reductase inhibitor*
- Warfarin is a vitamin K epoxide reductase inhibitor used for chronic anticoagulation
- It has a **slow onset of action** (days) and is inappropriate for acute STEMI management
- It is used for long-term anticoagulation in conditions like atrial fibrillation or mechanical heart valves, not for acute coronary syndromes requiring rapid platelet inhibition
Question 814: A 55-year-old man comes to the physician because of difficulties achieving an erection for the past year. A medication is prescribed that inhibits cyclic GMP phosphodiesterase type 5. Which of the following is the most likely site of action of the prescribed drug?
A. Corpus spongiosum
B. Pelvic splanchnic nerves
C. Pudendal nerve
D. Prostate smooth muscle
E. Corpus cavernosum (Correct Answer)
Explanation: ***Corpus cavernosum***
- **Erectile dysfunction** is primarily due to insufficient blood flow into the **corpus cavernosum**, which are the main erectile tissues of the penis.
- **cGMP phosphodiesterase type 5 (PDE5) inhibitors** like sildenafil work by increasing cGMP levels in the smooth muscle cells of the corpus cavernosum, leading to vessel relaxation and improved blood inflow.
*Corpus spongiosum*
- The **corpus spongiosum** primarily surrounds the urethra and prevents its compression during erection; it plays a secondary role in penile rigidity.
- While it does contain smooth muscle, it is not the primary target for medications aimed at enhancing penile rigidity.
*Pelvic splanchnic nerves*
- The **pelvic splanchnic nerves** are involved in the neural initiation of erection by releasing **nitric oxide (NO)**, which triggers cGMP production.
- However, the prescribed medication acts on the cGMP breakdown *within* the erectile tissue, not on the nerves that initiate the process.
*Pudendal nerve*
- The **pudendal nerve** is mainly responsible for carrying sensory information from the penis and innervating the external urethral sphincter and perineal muscles.
- It does not directly control the vascular smooth muscle relaxation necessary for erection, so it is not the site of action for PDE5 inhibitors.
*Prostate smooth muscle*
- While the **prostate** contains smooth muscle, it is not directly involved in the erectile process itself.
- Some PDE5 inhibitors are used for **benign prostatic hyperplasia (BPH)** symptoms by relaxing smooth muscle in the prostate and bladder neck, but this is a secondary effect distinct from their primary erectile function.
Question 815: A 30-year-old man presents to his psychiatrist for a follow-up visit. He was diagnosed with schizophrenia 6 months ago and has been taking fluphenazine. He says that his symptoms are well controlled by the medication, and he no longer has auditory hallucinations. The psychiatrist also notes that his delusions and other psychotic symptoms have improved significantly. However, the psychiatrist notices something while talking to the patient that prompts him to say, “I know the drug has effectively controlled your symptoms but I think you should discontinue it now otherwise this side effect is likely to be irreversible.” Which of the following did the psychiatrist most likely notice in this patient?
A. Choreoathetoid movements of face (Correct Answer)
B. Crossing and uncrossing legs constantly
C. Involuntary sustained twisting of neck
D. Resting tremors
E. Reduced spontaneous movements while walking
Explanation: ***Choreoathetoid movements of face***
- The psychiatrist is concerned about **tardive dyskinesia (TD)**, a late-onset side effect of dopamine receptor blocking agents like fluphenazine. Its hallmark symptoms include **choreoathetoid (involuntary, jerky, writhing) movements**, often affecting the face (e.g., lip smacking, grimacing, tongue protrusion).
- TD can become **irreversible** if the offending medication is continued, necessitating drug discontinuation to prevent permanent motor dysfunction.
*Reduced spontaneous movements while walking*
- This symptom, along with a "shuffling gait" and **bradykinesia**, is characteristic of drug-induced **Parkinsonism**.
- While concerning, Parkinsonism is generally **reversible** upon dose reduction or discontinuation of the antipsychotic, or with the addition of anticholinergic agents, making the psychiatrist's urgent warning about irreversibility less likely for this specific side effect.
*Crossing and uncrossing legs constantly*
- This behavior is indicative of **akathisia**, an inner sense of restlessness that manifests as an inability to sit still.
- Akathisia is a common extrapyramidal side effect that is typically **reversible** with dose reduction, medication change, or treatment with beta-blockers, and is not usually considered irreversible like tardive dyskinesia.
*Involuntary sustained twisting of neck*
- This describes **dystonia**, an extrapyramidal side effect characterized by sustained or repetitive muscle contractions leading to abnormal postures, such as **torticollis** (twisting of the neck).
- Dystonia, while distressing, is usually **reversible** with acute treatment (e.g., anticholinergics like benztropine) and medication adjustment, rarely becoming irreversible.
*Resting tremors*
- **Resting tremors** are a feature of drug-induced **Parkinsonism**, often accompanied by rigidity and bradykinesia.
- Similar to other Parkinsonian symptoms, these tremors are generally **reversible** with appropriate medication management and are not typically considered an irreversible side effect if the offending drug is discontinued promptly.
Question 816: A 72-year-old woman is brought to the emergency department by her son after he noticed that she was slurring her speech. He also noticed that she appeared to have difficulty using her fork about halfway through dinner when the speech problems started. He brought her to the emergency department immediately and he estimates that only 1 hour has passed since the beginning of the symptoms. An immediate exam is conducted. A medication is administered to ameliorate the effects of this patient's condition that would not be available for use if the patient had presented significantly later. An hour later the patient's condition becomes significantly worse and new deficits are found. Which of the following agents should be used at this point?
A. Protamine sulfate
B. Antivenin
C. Aminocaproic acid
D. Plasma transfusion (Correct Answer)
E. Vitamin K
Explanation: ***Plasma transfusion***
- The patient's clinical presentation (acute focal neurological deficits within 1 hour) indicates **ischemic stroke**, and the "medication administered to ameliorate effects...not available if presented significantly later" is **tissue plasminogen activator (tPA/alteplase)**, which must be given within 3-4.5 hours of symptom onset.
- The subsequent **worsening with new deficits** after initial tPA administration strongly suggests **hemorrhagic transformation** of the ischemic stroke, a known complication of thrombolytic therapy.
- **Fresh frozen plasma (FFP)** is the appropriate treatment because tPA depletes **fibrinogen and clotting factors** through systemic fibrinolysis, and FFP directly replaces these consumed clotting factors to help control bleeding.
- Management of tPA-related hemorrhage includes: stopping tPA, emergent neuroimaging, and administration of **cryoprecipitate** (to replace fibrinogen) and/or **FFP** (to replace clotting factors).
*Aminocaproic acid*
- **Aminocaproic acid** is an antifibrinolytic agent that inhibits plasminogen activation.
- While it can theoretically help in fibrinolytic-related bleeding, it is **NOT first-line therapy** for tPA-associated hemorrhagic transformation.
- **Cryoprecipitate and FFP** are preferred because they directly replace the fibrinogen and clotting factors depleted by tPA, addressing the underlying coagulopathy.
*Protamine sulfate*
- **Protamine sulfate** reverses **heparin** anticoagulation by binding to and inactivating heparin.
- This patient received tPA (a thrombolytic), not heparin, so protamine would not be effective.
*Antivenin*
- **Antivenin** is used to neutralize venom from snake or spider bites.
- This patient's presentation is consistent with stroke and tPA complication, not envenomation.
*Vitamin K*
- **Vitamin K** reverses **warfarin** by promoting hepatic synthesis of vitamin K-dependent clotting factors (II, VII, IX, X).
- Warfarin reversal takes hours to days; in acute bleeding, **FFP or prothrombin complex concentrate (PCC)** provides immediate factor replacement.
- This patient's complication is related to tPA (thrombolytic), not warfarin.
Question 817: A 35-year-old woman is started on a new experimental intravenous drug X. In order to make sure that she is able to take this drug safely, the physician in charge of her care calculates the appropriate doses to give to this patient. Data on the properties of drug X from a subject with a similar body composition to the patient is provided below:
Weight: 100 kg
Dose provided: 1500 mg
Serum concentration 15 mg/dL
Bioavailability: 1
If the patient has a weight of 60 kg and the target serum concentration is 10 mg/dL, which of the following best represents the loading dose of drug X that should be given to this patient?
A. 300 mg
B. 450 mg
C. 150 mg
D. 1000 mg
E. 600 mg (Correct Answer)
Explanation: ***600 mg***
- First, calculate the **volume of distribution (Vd)** using the provided data: **Vd = Total Dose / Serum Concentration**. Converting units: 15 mg/dL = 150 mg/L. Therefore, Vd = 1500 mg / 150 mg/L = **10 L** (for the 100 kg subject).
- Since the Vd value is for a 100 kg person, Vd per kg = 10 L / 100 kg = **0.1 L/kg**. For the 60 kg patient, the Vd = 0.1 L/kg × 60 kg = **6 L**.
- The **loading dose = Target Serum Concentration × Vd / Bioavailability**. Converting target concentration: 10 mg/dL = 100 mg/L. Therefore: (100 mg/L × 6 L) / 1 = **600 mg**.
*300 mg*
- This value is obtained if an incorrect **Vd** or target concentration was used, potentially through miscalculation or incorrect unit conversion.
- For instance, if the **Vd** was inaccurately calculated at 3 L (instead of 6 L), this could lead to the incorrect answer.
*450 mg*
- This result might occur if the **Vd calculation** was flawed or if the target concentration was incorrectly interpreted.
- A potential error could involve using a Vd of 4.5 L which would result in 450 mg, or if the drug amount was simply prorated by weight without properly considering the Vd per kg.
*150 mg*
- This value suggests a significant error in the calculation of the **volume of distribution** or the target concentration.
- It might be obtained if the **Vd** was mistakenly taken as 1.5 L or if the dose was divided by the original serum concentration without accounting for the new patient's weight and desired concentration.
*1000 mg*
- This value is significantly higher than the correct answer, indicating an overestimation of the **Vd** or target concentration.
- It could result from using the original dose (1500 mg) and attempting to scale it incorrectly by weight alone (1500 mg × 60/100 = 900 mg, close to 1000), or if unit conversions were mishandled during the Vd determination.
Question 818: A 36-year-old man is brought to the emergency department by his girlfriend because of increasing confusion for the past 6 hours. He drinks large amounts of alcohol daily and occasionally uses illicit drugs. He is lethargic and oriented only to person. Physical examination shows jaundice, hepatomegaly, and scattered petechiae over the trunk and back. Neurologic examination shows normal, reactive pupils and a flapping tremor when the wrists are extended. A drug with which of the following mechanism of action would be most appropriate for this patient's condition?
A. Production of NH3
B. Activation of GABA receptors
C. Excretion of free iron
D. Inhibition of D2 receptors
E. Excretion of NH4 (Correct Answer)
Explanation: ***Excretion of NH4***
- The patient presents with **hepatic encephalopathy**, characterized by **confusion**, **jaundice**, **hepatomegaly**, **petechiae**, and a **flapping tremor (asterixis)**, stemming from chronic alcohol abuse and liver damage. The main pathophysiology in hepatic encephalopathy is the accumulation of **ammonia (NH3)**, which is neurotoxic.
- Excretion of **NH4** (ammonium) through drug mechanisms such as **lactulose** (which acidifies the colon, trapping ammonia as ammonium for excretion) is the primary therapeutic target to reduce ammonia levels and improve neurological symptoms.
*Production of NH3*
- This mechanism would exacerbate the patient's condition by increasing the toxic load of **ammonia (NH3)**, which is already elevated in hepatic encephalopathy.
- Therapeutic interventions aim to decrease, not increase, ammonia production or absorption.
*Activation of GABA receptors*
- While **GABA receptor activation** is involved in the neurological effects of some substances that contribute to confusion, it is not the primary target for treating the underlying pathophysiology of **hepatic encephalopathy**.
- Medications that activate GABA receptors (e.g., benzodiazepines) can worsen encephalopathy by further depressing CNS function.
*Excretion of free iron*
- **Iron overload** can cause liver damage, but the acute confusion and flapping tremor are more indicative of **hepatic encephalopathy** due to ammonia toxicity, not primarily iron accumulation.
- Excreting free iron (e.g., with chelation therapy) is for conditions like hemochromatosis and would not address the immediate, life-threatening neurological symptoms in this patient.
*Inhibition of D2 receptors*
- This mechanism is characteristic of some **antipsychotic medications**. While dopamine imbalances can play a role in some neurological disorders, inhibiting D2 receptors is not a primary therapeutic target for **hepatic encephalopathy**.
- Such medications could have side effects that might complicate the clinical picture in a patient with acute liver failure.
Question 819: A 25-year-old G1P0 woman at an estimated gestational age of 9 weeks presents for her first prenatal visit following a positive home pregnancy test. She says she missed 2 periods but assumed it was due to stress at work. She has decided to continue with the pregnancy. Her past medical history is significant for migraine headaches, seizures, and asthma. She takes multiple medications for her condition. Physical examination is unremarkable. An ultrasound confirms a 9-week-old intrauterine pregnancy. Which of the following medications poses the greatest risk to the fetus?
A. Valproic acid (Correct Answer)
B. Budesonide
C. Acetaminophen
D. Sumatriptan
E. Albuterol
Explanation: ***Valproic acid***
- **Valproic acid** is a known **teratogen** strongly associated with a high incidence of **neural tube defects** (e.g., spina bifida, anencephaly) when used during the first trimester of pregnancy.
- It can also lead to other malformations, including cardiac defects and facial dysmorphism, as part of **fetal valproate syndrome**.
*Budesonide*
- **Budesonide** is an inhaled corticosteroid commonly used for asthma, considered a relatively **safe medication** during pregnancy (FDA pregnancy category B).
- Studies have shown no increased risk of major congenital malformations with its use.
*Acetaminophen*
- **Acetaminophen** is a widely used analgesic and antipyretic considered **safe** for use throughout pregnancy at recommended doses.
- There is no strong evidence linking acetaminophen to an increased risk of birth defects.
*Sumatriptan*
- **Sumatriptan** is a serotonin receptor agonist used for migraine headaches. It is generally considered to be of **low risk** during pregnancy (FDA pregnancy category C).
- While some studies have suggested a minimal risk of certain birth defects, overall data supports its use when necessary.
*Albuterol*
- **Albuterol** is a short-acting beta-agonist used to treat asthma symptoms and is considered **safe** for use during pregnancy (FDA pregnancy category C).
- There is no evidence of teratogenicity, and the benefits of controlling asthma outweigh the potential risks.
Question 820: A 62-year-old woman with a history of subarachnoid hemorrhage is brought to the emergency department because of shortness of breath and sharp chest pain that worsens on inspiration. She underwent surgery for a hip fracture 3 weeks ago. Her pulse is 110/min, respirations are 20/min, and blood pressure is 112/74 mm Hg. Pulse oximetry on room air shows an oxygen saturation of 92%. The lungs are clear to auscultation and there is no jugular venous distention. A ventilation and perfusion scan shows a small perfusion defect in the left lower lung. A drug with which of the following mechanisms of action is most appropriate for this patient?
A. Inhibition of adenosine diphosphate receptors
B. Activation of plasminogen
C. Inhibition of cyclooxygenase
D. Inhibition of vitamin K epoxide reductase
E. Activation of antithrombin III (Correct Answer)
Explanation: ***Activation of antithrombin III***
- The patient's symptoms (shortness of breath, sharp chest pain worsening on inspiration, tachycardia, tachypnea, hypoxia) and history (hip fracture surgery 3 weeks ago, subarachnoid hemorrhage) are highly suggestive of a **pulmonary embolism (PE)**, further supported by the perfusion defect on V/Q scan.
- **Heparin**, which activates antithrombin III, is the most appropriate initial therapy for PE because of its rapid onset of action and ability to prevent further clot formation, especially given the patient's history of subarachnoid hemorrhage, which contraindicates thrombolytics unless absolutely necessary for hemodynamic instability.
*Inhibition of adenosine diphosphate receptors*
- Drugs that inhibit ADP receptors, such as **clopidogrel**, are **antiplatelet agents** used to prevent arterial clots (e.g., in myocardial infarction or stroke).
- They are not the primary treatment for an acute venous thromboembolism like a pulmonary embolism, which requires anticoagulation to prevent further fibrin formation.
*Activation of plasminogen*
- **Thrombolytic agents** (e.g., tissue plasminogen activator) activate plasminogen to dissolve existing clots.
- While effective in severe PE, their use is associated with a high risk of bleeding, especially in a patient with a recent history of **subarachnoid hemorrhage**, making them contraindicated in this scenario unless the patient is hemodynamically unstable.
*Inhibition of cyclooxygenase*
- **Aspirin** inhibits cyclooxygenase (COX), reducing prostaglandin and thromboxane A2 synthesis, thereby inhibiting platelet aggregation.
- It is an **antiplatelet agent** primarily used for arterial thrombosis prophylaxis and is not the first-line treatment for acute pulmonary embolism.
*Inhibition of vitamin K epoxide reductase*
- Drugs like **warfarin** inhibit vitamin K epoxide reductase, which interferes with the synthesis of vitamin K-dependent clotting factors.
- Warfarin is used for long-term anticoagulation, but its **slow onset of action** makes it unsuitable for acute management of pulmonary embolism; heparin is typically initiated first.
